This report presents an initial analysis conducted in August 2024 and finalized in December 2024, covering the literature review and monitoring of risk trends in Latin America. Based on the current state of knowledge at the time of writing, infection with the Oropouche virus (OROV) is one of the most significant causes of arbovirus disease in South America after dengue, with 2 to 5 million people directly exposed. This significance contrasts with the fragmented or imprecise knowledge regarding the transmission cycle, vectors, animal hosts and reservoirs, clinical aspects, asymptomatic forms, and the epidemiology of OROV infection. OROV is a segmented virus belonging to the Orthobunyaviridae family, with significant potential for evolution and emergence, particularly due to its ability to reassort. The outbreak and epidemic spread observed in 2023–2024 (including the Caribbean) are linked to a reassorted virus, with the first-ever reports of deaths and maternal-fetal cases involving malformations, as well as a possible risk of sexual transmission. The virus has expanded its circulation area under the influence of changes in the environment and biodiversity, demographic trends, and human mobility. The known primary vector and potential vectors have a much wider distribution than current outbreaks, particularly in French Guiana and Martinique. The risk of importation via travel and spread within the French Overseas Collectivities (CFAs) was estimated to be high in August and December 2024. Culicoides midges, which transmit Orbiviruses and Orthobunyaviruses to domestic and wild ruminants (Bluetongue [BT], epidemic hemorrhagic disease (EHD), Schmallenberg virus disease [SBV]) can be dispersed by winds over very long distances across bodies of water and thus be responsible for introducing viruses into disease-free areas. This mode of transmission should be studied for C. paraensis in the context of OROV transmission. The risk of OROV human infection emerging in the CFAS was assessed in this report for all CFAS except Saint Martin and Saint Barthélemy due to a lack of data. The report concludes that there is a high risk of an epidemic in French Guiana, Martinique, and Guadeloupe, with high uncertainty in this analysis for French Guiana and Martinique and low uncertainty for Guadeloupe. The significant increase in risk for the CFAs in 2024 underscores the need for preparedness, including management measures. Among these, short-term measures focus particularly on diagnostic capacity, surveillance and early warning, individual and collective protection against vectors, as well as epidemiological and entomological investigations. The risk level estimated in August 2024 will need to be updated for the CFAs in the coming months based on the evolution of the epidemic in South America and the Caribbean. There is no specific treatment or vaccine against Oropouche virus disease, and treatment is symptomatic.